Other Events ·
Jupiter Neurosciences, Inc. entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings…
JUNSJupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. to obtain exclusive U.S. rights to the ALA-002 program. The agreement includes an aggregate upfront payment of $3,333,333, consisting of $1,500,000 in cash and $1,833,333 in Jupiter common stock. Additionally, the company will pay up to $23,333,333 in development milestones and up to $73,333,333 in commercialization milestones, plus a 3% royalty on net sales. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and CNS disorders.